EWM
FLGT icon

Executive Wealth Management’s Fulgent Genetics FLGT Stock Holding History

Executive Wealth Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,194
Closed -$211K – 196
2021
Q1 		$211K Buy
+2,194
New +$226K 0.02% 182

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Executive Wealth Management's FLGT Position: Q2 2021 in Review

Executive Wealth Management sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 2,194 shares — an estimated $211K sold.

Executive Wealth Management first reported a position in FLGT in Q1 2021 and held it in 1 quarter. The position peaked at $211K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

  • Executive Wealth Management reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
  • Executive Wealth Management sold 2,194 Fulgent Genetics shares in Q2 2021, an estimated $211K.
  • Executive Wealth Management first reported a position in Fulgent Genetics in Q1 2021 and held it in 1 quarter.
  • Executive Wealth Management's Fulgent Genetics position peaked at $211K in Q1 2021.
  • 254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Executive Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.